Expression of CRM1 and CDK5 shows high prognostic accuracy for gastric cancer

Figure 1 Eligibility criteria for patient inclusion.

Figure 2 Immunohistochemical staining of CRM1 and CDK5 expression in gastric cancer tissue and the criteria for immunohistochemistry scoring. Score 0: no staining, Score 1: weak staining, Score 2: moderate staining, Score 3: strong staining. The protein expression was considered low if the score was ≤ 1 and high if it was ≥ 2. Scale bar = 100 μm.

Figure 3 Forest plot showing hazard ratios (oblongs) and 95%CI (bars) for overall survival of subgroups from the 240 gastric cancer patients with different CRM1 (left) and CDK5 (right) expression status. HR: Hazard ratio; OS: Overall survival; CRM: Chromosomal maintenance; CDK: Cyclin-dependent kinase.

Figure 4 Kaplan-Meier analysis of the correlation between expression of CRM1 (A), CDK5 (B) and combined CRM1 and CDK5 expression (C) and the overall survival of gastric cancer patients. CRM: Chromosomal maintenance; CDK: Cyclin-dependent kinase.

Figure 5 Receiver operating characteristic analysis of the sensitivity and specificity of the predictive value of the combined CRM1 and CDK5 expression model, CRM1 expression model and CDK5 expression model. CRM: Chromosomal maintenance; CDK: Cyclin-dependent kinase.